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Abstract
G-protein coupled receptors (GPCRs) participate in a wide range of vital regulations of our physiological actions. They are
also of pharmaceutical importance and have become many therapeutic targets for a number of disorders and diseases.
Purified GPCR-based approaches including structural study and novel biophysical and biochemical function analyses are
increasingly being used in GPCR-directed drug discovery. Before these approaches become routine, however, several
hurdles need to be overcome; they include overexpression, solubilization, and purification of large quantities of functional
and stable receptors on a regular basis. Here we report milligram production of a human formyl peptide receptor 3 (FPR3).
FPR3 comprises a functionally distinct GPCR subfamily that is involved in leukocyte chemotaxis and activation. The
bioengineered FPR3 was overexpressed in stable tetracycline-inducible mammalian cell lines (HEK293S). After a systematic
detergent screening, fos-choline-14 (FC-14) was selected for subsequent solubilization and purification processes. A two-
step purification method, immunoaffinity using anti-rho-tag monoclonal antibody 1D4 and gel filtration, was used to purify
the receptors to near homogeneity. Immunofluorescence analysis showed that expressed FPR3 was predominantly
displayed on cellular membrane. Secondary structural analysis using circular dichroism showed that the purified FPR3
receptor was correctly folded with .50% a-helix, which is similar to other known GPCR secondary structures. Our method
can readily produce milligram quantities of human FPR3, which would facilitate in developing human FPR as therapeutic
drug targets.
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Introduction
G-protein coupled receptors (GPCRs), also referred to as seven-
transmembrane (7TM) domain receptors, although functionally
diverse, constitute the largest integral membrane protein family in
the human genome [1–3]. Members of GPCR family share a
common topological structure on cellular membrane that contains
7 transmembrane helices with an extracellular N-terminus and an
intracellular C-terminus connected by three intracellular loops and
three extracellular loops [1,2]. Based on sequence homology,
ligand structure or receptor function, GPCRs are classified into
more than one hundred subfamilies. These receptors are
physiologically important in humans, participating in the regula-
tion of most of our physiological actions such as neurotransmis-
sion, enzyme release, chemotaxis or inflammation, as well as our
sense of vision, smell and taste, by sensing endogenous or
environmental stimuli through binding compatible ligands and
transducing corresponding signal into cells typically through
coupled heterotrimeric G protein. Hence GPCRs are the most
frequently addressed therapeutic targets for a number of disorders
and diseases. Currently ,50% of all prescription drugs and ,66%
of drugs in development are targets for GPCRs [3–5].
Formyl peptide receptors (FPRs) comprise a functionally distinct
GPCR subfamily involved in leukocyte chemotaxis and activation. In
human and other primates, 3 FPR subtypes have been identified [6].
The first defined human FPR gene, FPR1 (www.uniprot.org/
uniprot/P21462), was initially reported as a high affinity binding
site on the surface of neutrophils for the prototypic N-formyl peptide
formyl-methionine-leucine-phenylalanine (fMLF) and then its gene
was cloned in 1990 from a differentiated HL-60 myeloid leukemia-
cell cDNA library [7,8]. Two additional human FPRs, designated
FPR2 (www.uniprot.org/uniprot/P25090) and FPR3 (www.uniprot.
org/uniprot/P25089), were subsequently cloned by low-stringency
hybridization using the FPR1 cDNA as a probe. These FPR genes
are shown to cluster on human chromosomal region 19q13.3 [9–11].
Functionally, these receptors are considered to play important roles
in innate immunity and host defense mechanisms, including immune
response to microorganism infection, proinflammatory response in
amyloidogenic diseases, host responses to cell necrosis and apoptosis
and so on [6,12,13]. These receptors may also influence the expression
and function of CCR5 and CXCR4 on human monocytes, two major
GPCR chemokine coreceptors of human immunodeficiency virus type
1 (HIV-1) [14,15]. Moreover, human FPR expression has been
observed in numerous distinct tissues and cell types ([6–7] and
references therein), indicating a much broad distribution of these
receptors and their physiologically significant role in vivo. Hence FPRs
comprise an appealing group of therapeutic targets, most importantly,
for infectious and immunologically mediated diseases.
We selected FPR3 for our study because a peptide ligand is known
for FPR3. Also FPR3 shares 56% and 83% amino acid sequence
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identity to FPR1 and FPR2, respectively. Interestingly, the FPR3
does not respond to fMLF, the prototypic N-formyl peptide usually
generated at sites of bacterial infection or tissue injury, while FPR1
binds fMLF with high affinity and FPR2 does with low affinity
[16,17]. This phenomenon indicates that the N-formyl group is not
essential for ligand binding to human FPRs. In addition, compared to
FPR1 and FPR2, a small number of ligands for FPR3 have been
identified, among which is an endogenous acetylated peptide F2L.
This F2L appears to be the most specific ligand that binds and
activates FPR3 in the low nanomolar range [18]. Ongoing efforts are
still required to further expand the ligand spectrum of FPR3, to
decipher the underlying structural and functional mechanisms of
FPR3 as well as two other human FPRs, and to eventually identify
novel pharmacologically relevant interacting partners.
The classical techniques employed in GPCR-directed drug
discovery are chiefly cell-based assays combined with high
throughput screening (HTS) method. These techniques are suited
to measure GPCR ligand binding, G-protein function and second
messenger generation, and GPCR downstream signaling [19]. As
an alternative to the cell-based assays, purified GPCR-based
approach becomes increasingly attractive in GPCR-directed drug
discovery. By using stabilized pure GPCRs, diffraction-quality
protein crystals can be obtained, which would lead to an insight into
GPCR structure that may eventually identify each unique
functional property. Although this is a challenging goal, 6 molecular
structures of GPCRs have been resolved, including bovine
rhodopsin [20,21], human b2-adrenergic receptor [22,23], avian
b1-adrenergic receptor [24] and human A2A adenosine receptor
[25], human CXCR4 [26] and human dopamine D3 receptor [27].
The availability of additional GPCR structures, along with novel
biophysical and biochemical approaches to directly study purified
GPCRs, would help gain a deep understanding of GPCRs’ structure
and function relationship, and also further stimulate drug screening
and structure-based drug design [28].
In order to carry out study of FPR3 as well as purified protein-
based biophysical and biochemical function analyses, large
quantities of active and stable receptors are required. Because of
the extremely low abundance of most GPCRs in their natural
environments, overexpression in heterologous host systems is a
prerequisite for large quantity production.
Here we report the expression and purification of a bioengi-
neered human FPR3 from stable tetracycline-inducible HEK293S
cell lines, a heterologous expression system suitable for large-scale
GPCR protein productions [29–31]. After a systematic detergent
screening, fos-choline-14 (FC-14) was selected for subsequent
solubilization and purification processes. Our previous study
identified FC14 as one of the best detergents [30–32]. A two-
step purification method using monoclonal antibody immunoaffi-
nity purification and gel filtration was employed to purify the
receptors to near homogeneity. Immunofluorescence analysis
indicated that expressed FPR3 was predominantly distributed on
cellular membrane. Furthermore secondary structural analysis
using circular dichroism (CD) showed that the purified FPR3
receptors were correctly folded with .50% a-helical content,
which is consistent with other known GPCR a-helical content.
Using this method, we obtained milligram quantities of human
FPR3, which would be used for further studies.
Results
Construction of stable human FPR3-inducible HEK293S
cell lines
The stable human FPR3-inducible HEK293S cell lines [29–31]
were constructed using the Invitrogen T-REx tetracycline
regulation system as described before [29–30]. In all, 30 clones
were screened for FPR3 expression for selecting stable cell lines.
Figure 1 shows the Western blot analysis result of FPR3 expression
in clone 1, clone 14 and clone 15, respectively, which among all
the clones showed the highest expressions after 48-hour induction
in media supplemented with 1 mg/ml tetracycline. It can be seen
that in these 3 clones, no apparent background levels are detected
by Western blot analysis using anti-rho-tag monoclonal antibody
1D4 in the absence of tetracycline induction. Whereas, FPR3
expression of clone 14 and clone 15 was more enhanced after
induction using tetracycline combining with sodium butyrate than
using tetracycline alone. The positive synergistic effect of sodium
butyrate on expression, when used with tetracycline regulation
system, has been demonstrated previously in the study of several
other GPCRs [29–31].
Western blot analysis using a monoclonal antibody against the
C-terminal rho-tag 1D4 tag also revealed two immunoreactive
monomeric FPR3 bands in both clone 1 and clone 14, which
migrated at approximately 38 kDa and 42 kDa, respectively,
indicated by arrows. Although the bioengineered FPR3 has a
theoretical molecular weight of 42.4 kDa, however, it is common
that two monomeric FPR3 forms migrate slightly faster than
expected on SDS-PAGE gel, like many other membrane proteins
[29–31]. For both clone 1 and clone 14, while the 42 kDa band
predominated after 48-hour induction in media supplemented
with 1 mg/ml tetracycline, the 38 kDa band predominated over
the 42 kDa band after 48-hour induction in media supplemented
with 1 mg/ml tetracycline plus 2.5 mM sodium butyrate. Similar
Figure 1. Construction of stable human FPR3-inducible
HEK293S cell lines using the T-REx system (Life Technologies).
Clones were tested for induction after 48 h in plain media (2) or media
supplemented with 1 mg/ml tetracycline (+) or tetracycline plus 2.5 mM
sodium butyrate enhancer (++). Arrows indicate the positions of the 38-
and 42-kDa monomer forms. Levels of human FPR3 were probed via
Western blot analysis against the rho1D4 tag at the C-terminus of the
protein sequence. Clones 1, 14 and 15 show highest levels of induction
while maintaining undetectable background levels in the absence of
tetracycline. Clone 15 that only expressed the 42-kDa FPR3 monomer
was selected for subsequent experiments.
doi:10.1371/journal.pone.0023076.g001
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phenomena have been observed in our previous study of another
GPCR of human olfactory receptor 17-4 [30–31].
By contrast, for clone 15, the 42 kDa is the only visible band
under both induction conditions. Clone 15 also produced much
less dimeric and oligomerized FPR3 receptors than clone 1 and
clone 14, as revealed on the upper part of corresponding lanes.
Because protein heterogeneity could potentially interfere with
future crystallization and structural study, we thus only selected
clone 15 for all subsequent experiments. The concentrations of
tetracycline and sodium butyrate were also optimized with respect
to FPR3 expression level for clone 15. A combination of 1 mg/ml
tetracycline and 2.5 mM sodium butyrate was optimal for FPR3
expression, and thus this induction condition was selected for all
subsequent expressions.
Detergent screening of human FPR3 solubilization from
HEK293S cells
The selection of a suitable detergent for membrane protein
solubilization from cellular membrane and its stabilization is
crucial not only for subsequent purification process, but also for
membrane protein activity preservation and the final protein yield.
However, our understanding of the interaction between detergents
and membrane proteins is still limited, and currently the choice of
a detergent is mostly empirical. Indeed an elaborate and laborious
screening process is required to select an optimal detergent, which
usually results in membrane protein-specific optimization.
Although fos-choline series were found most effective for
solubilizing and stabilizing several other GPCRs after systematic
detergent screening in our lab [30–32], it still remained unknown
if these detergents would work well for human FPR3 receptors.
Thus, we again carried out a systematic detergent screening that
included representatives from non-ionic, anionic, cationic and
zwitter-ionic detergent classes, and some detergent mixtures that
are proven effective for solubilizing other GPCRs.
The detergent screening result is shown in Figure 2, with 96
detergents/detergent mixtures screened and their solubilization
ability quantified by spot densitometry. The 3 best detergents
found most effective for solubilizing the FPR3 included Fos-
choline-unsat-11-10 (zwitter-ionic), Anapoe-X-100 (non-ionic) and
Fos-choline-14 (zwitter-ionic). Again, Fos-choline-unsat-11-10 and
Fos-choline-14 (FC-14) from fos-choline series were shown to be
very effective for solubilizing the FPR3 receptors from HEK293S
cells, which are structurally related to phosphatidylcholine (PC), a
phospholipid and major constituent of the lipid bilayer of
mammalian cells.
In order to act as an effective solubilizer for membrane protein
study, a detergent must be used at concentrations above its critical
micelle concentration (CMC), namely, the minimal concentration
required for detergent monomers to self-assemble into non-
covalent micelles. In general, the CMC dictates how much
detergent is needed in the solubilization and stabilization of
membrane protein. Fos-choline-unsat-11-10 has a high CMC
value of 0.21%, although it is found to be the most effective
detergent among the 96-detergents/detergent mixtures screened
in this study. In contrast, Anapoe-X-100 and FC-14 also very
effective for solubilizing the FPR3 have much lower CMC values
of 0.015% and 0.0046%, respectively. For consideration of cost-
effectiveness in detergent usage, FC-14 was selected for all
subsequent solubilization and purification, which was also used
in our previous studies of other GPCRs and shown also very
effective for stabilizing GPCRs [30–32].
Purification of human FPR3 produced from HEK293S cells
The purification of solubilized receptors is another major
obstacle to overcome in large-quantity GPCR protein production.
It is usually very difficult to achieve efficient purification if using
conventional ion-exchange chromatography. In this study, we
used a two-step purification method comprising first immunoaffi-
nity purification and then gel filtration to purify the FC-14
solubilized FPR3 receptors, which was shown to be highly efficient
in the purification of other GPCRs [30–32]. For the first
immunoaffinity purification step, CNBr-activated Sepharose 4B
beads linked to the mouse monoclonal rho1D4 antibody were used
to capture FC-14 solubilized FPR3. Following a thorough wash
Figure 2. Detergent screening for optimal solubilization of human FPR3 expressed in HEK293S cells. Expression of the FPR3 was
induced with tetracycline (1 mg/ml) and sodium butyrate (2.5 mM) for 48 h and receptors were solubilized in PBS containing detergent(s) for 1 h at
4uC. In total, 96 detergents/detergent mixtures were screened in this study. Each integer from 1 to 96 along x-axis represents a detergent/detergent
mixture (see Table S1 for more information about each detergent/detergent mixture). The ability of screened detergents/detergent mixtures to
solubilize the FPR3 has been quantified by spot densitometry and normalized to the range from 0.0 to 1.0 for ease of comparison.
doi:10.1371/journal.pone.0023076.g002
Production of Human Formyl Peptide Receptor 3
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23076
procedure to remove non-specific impurities, the captured
receptors were eluted by the addition of an excess of rho1D4
elution peptide (TETSQVAPA). Western blot analysis indicated
that the receptors eluted primarily in the first 3-elution fractions
after being captured completely by the rho1D4 antibody bead
matrix.
To further purify the receptor and to remove the elution
rho1D4 peptide, the elution fractions from immunoaffinity
purification were concentrated and then subjected to gel filtration
on a A¨kta HPLC system. Column flow-through was monitored by
UV absorption (280 nm, 254 nm and 215 nm) and separated into
fractions by an auto-fraction collector. Shown in Figure 3A is the
chromatogram of gel filtration on immunoaffinity-purified human
FPR3 from ,6 g induced HEK293S cells [29–31], in which
several distinct peaks can be observed. The peak fractions were
then pooled, concentrated and subjected to SDS-PAGE followed
by Western blot and total protein staining. Figure 3B shows the
result of protein staining analysis on the peak fractions. Peak 2
contained predominantly monomeric FPR3 (.90% purity) and
also a very small amount of dimeric FPR3. Earlier peak 1
contained no samples that could be detectable by total protein
staining. The later peaks 3 and 4 mainly contained monomeric
FPR3 and a truncated form of FPR3 (,15 kD). Peak 5 contained
the rho1D4 elution peptide from the immunoaffinity purification.
The final yield of purified FPR3 monomer was ,2 mg. Thus,
using a simple two-step method, we have successfully obtained 2
milligrams of human FPR3.
Cellular localization of human FPR3 using
Immunofluorescence
Cell-based immunofluorescence analysis was also performed to
verify the distribution of expressed FPR3 on cellular membrane.
First, HEK293S cells [29–31] were induced for 48-hour in media
supplemented with 1 mg/ml tetracycline plus 2.5 mM sodium
butyrate. The cells were then fixed and permeabilized, followed by
blocking with bovine serum albumin. Mouse monoclonal rho1D4
antibody was then applied to HEK293S cells, followed by Alexa
Fluor 488 goat anti-mouse antibody. Cells were then examined
using excitation at 488 nm. Figure 4 shows the immunofluores-
cence images of induced HEK293S cells. Enhanced fluorescence
can be seen around the edge of the cells, indicating the expressed
FPR3 was predominantly distributed on plasma membrane.
Secondary structural studies using circular dichrism of
purified human FPR3
We next asked whether the purified, FC-14-solubilized human
FPR3 retained properly folded secondary structure. The a-helical
feature of GPCRs has been confirmed by the known molecular
structures with high resolution [20–27]. The computer prediction
for wild-type human FPR3 secondary structure, based on a free
web based transmembrane domain calculations, www.uniprot.
org/uniprot/P25089, is ,43% a-helix. 0 When we measured the
FPR3 using far-UV CD spectroscopy, the monomeric FPR3
displayed a spectrum characteristic of a predominantly character-
istic a-helical protein with minima at 208 nm and 222 nm
(Figure 5A). Analysis of the spectrum using the K2D2 algorithm
(www.ogic.ca/projects/k2d2/) showed that FPR3 has ,57% a-
helical content. This a-helical content is higher than the computer
predicted value. This higher value is likely from the contribution of
other a-helical segments in addition to the standard 7-transmem-
brane domains. Likewise, several distinct profiles were observed in
near-UV CD spectroscopy (Figure 5B), which suggests a defined
tertiary structure for the FPR3. It is known that the functional
bovine rhodopsin also has similar near-UV profile in this region;
whereas nonfunctional opsin mutants show flat spectra character-
istic of a misfolded globular state [33]. Thus both far-UV and
near-UV CD spectra suggest that the bioengineered human FPR3
Figure 3. A) Gel filtration on immunoaffinity-purified human
FPR3 from ,6 g cells (wet weight). Absorbance was recorded at
280 nm (black line), 254 nm (gray line), and 215 nm (dashed line). Peak
1–4 (indicated by numbers) were pooled and concentrated. Peak 5
contained the rho1D4 elution peptide TETSQVAPA from the immu-
noaffinity purification. B) Silver staining of the peak fractions. Peak
numbers refer to those designated in (A).
doi:10.1371/journal.pone.0023076.g003
Figure 4. Immunofluorescence analysis of cell surface ex-
pressed human FPR3. HEK293S cells were induced for 48 h in media
supplemented with 1 mg/ml tetracycline plus 2.5 mM sodium butyrate.
Cell images were taken after being fixed and incubated with
monoclonal anti-rho1D4 antibody followed by Alexa Fluor 488 goat
anti-mouse antibody.
doi:10.1371/journal.pone.0023076.g004
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folded correctly after purification and is suitable for subsequent
structural and functional studies.
Discussion
Formyl peptide receptors (FPRs) comprise a functionally distinct
GPCR subfamily involved in leukocyte chemotaxis and activation.
The broad tissue distribution of human FPRs and their potential
physiological roles make them an appealing group of therapeutic
targets, most importantly, for infectious and immunologically
mediated diseases.
Currently, as an alternative to the cell-based assays, purified
GPCR-based approach is increasingly being used in GPCR-
directed drug discovery. To initiate structural study and
biophysical and biochemical analyses directly exploiting purified
proteins for FPR-focused drug discovery, large-quantity produc-
tion is often required.
In this study, we successfully constructed human FPR3-
inducible mammalian cell lines and produced milligram quantities
of high quality FPR3 receptors following the method utilized for
large-scale production of hOR17-4 [30–31]. To our knowledge,
this is the first time a human FPR has been heterologously
expressed and purified in millilgrams.
To achieve receptor overexpression but minimize the toxic
effects, the stable human FPR3-inducible HEK293S cell lines [29–
31] were first constructed using the Invitrogen T-REx tetracycline
regulation system as described before [29–31]. This allowed the
HEK293S cells [29–31] to be grown to the desired density, when
needed, production of freshly produced receptor can be induced
by the addition of tetracycline. Thus structurally and functionally
homogenous FPR3 receptors could be obtained. Without tight
regulation system, the receptor production may be compromised
due to constitutive expression in HEK293S cells [29–31]. To
achieve receptor overexpression, altogether 30 clones were
screened and compared, among which clone 1, clone 14 and
clone 15 gave the highest expressions under the same induction
condition. For all clones screened, there is no background
expression detectable by Western blot analysis in the absence of
tetracycline, thus verifying the tightness of the tetracycline
regulation system.
It is interesting to notice that the FPR3 monomer expressed in
clone 1 and clone 14 migrated as a doublet at approximately
38 kDa and 42 kDa. Both monomer forms of the expressed FPR3
receptor are believed to be intact, full-length proteins, since both of
them were detected by the C-terminal rho1D4 monoclonal
antibody. In our previous study on hOR17-4 production, two
monomeric hOR17-4 bands were also detected, which was
demonstrated to be caused by glycosylation as this size discrepancy
was eliminated by mutation of the glycosylation site [30–31]. The
size discrepany of expressed FPR3 monomers is likely also caused
by glycosylation and the 42 kDa band possibly constituted a
glycosylated form of the receptor. Actually, human FPR3 is
predicted to have 3 N-glycosylation sites [34] and it is possible that
glycosylation occurred at more than one potential sites in the
42 kDa FPR3 monomer, which as a result shows a 4 kDa size
difference from the 38 kDa monomer. However, further studies
are required to fully elucidate the size discrepany of expressed
FPR3 monomers.
Moreover, for both clone 1 and clone 14, while the 42 kDa
band predominated after induction with tetracycline alone, the
38 kDa band predominated over the 42 kDa band after induction
with tetracycline plus sodium butyrate. One explanation is that in
clone 1 and clone 14, most receptors are glycosylated after
induction with tetracycline alone but the use of sodium butyrate in
conjunction with tetracycline, which usually leads to more rapid
and higher expression, results in the accumulation of FPR3
receptors in the endoplasmic reticulum (ER) and improper
processing of the receptors. Similar phenomenon has been
observed previously in the induction of hOR17-4 [30–31].
Nevertheless, we observed that such expression mode is cell line-
dependent for FPR3 induction. For example, clone 15 also giving
high expression level only expressed 42 kDa monomer under both
induction conditions tested. Since protein heterogeneity could
pose a problem for future crystallization and structural study, we
thus choose clone 15 for all subsequent experiments. As loss of
glycosylation has bee demonstrated to affect the function of
Figure 5. Secondary structural study of the purified human FPR3 monomer using both far-UV and near-UV CD spectroscopy. Mean
residue ellipticity [h] has units of degree6cm26dmol21. A) Far-UV CD spectrum of FPR3 displaying secondary structure of ,57% a-helix. B) Near-UV
CD spectrum of FPR3 showing distinct tertiary structure profiles. Spectra shown are the average of 3 replicate scans.
doi:10.1371/journal.pone.0023076.g005
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rhodopsin [35], the selection of clone 15 to exclusively express
42 kDa FPR3 monomer that is potentially glycosylated may better
suit functional study as well.
Following construction of stable cell lines overexpressing FPR3
receptors suitable for structural and functional studies, the
selection of an appropriate detergent is also crucial to subsequent
purification, protein activity preservation and the final protein
yield. After a systematic detergent screening, several detergents
were found most effective for solubilizing the FPR3, including Fos-
choline-unsat-11-10 and FC-14 from fos-choline series. However,
FC-14 was eventually selected for FPR3 solubilization from
HEK293S cells [29–31] and its subsequent purification out of
consideration for both solubilization- and cost-effectiveness in
detergent usage. The latter consideration is based on detergent
CMC, the minimal concentration above which a detergent must
be used to act as an effective solubilizer in membrane protein study
and which as a result also dictates predominantly how much
detergent is needed. So far, foscholine series were found very
effective for solubilizing and stabilizing all the GPCRs studied in
our lab [30–32] and by others [36], which are structurally related
to phosphatidylcholine (PC), a phospholipid and major constituent
of the lipid bilayer of mammalian cells. Thus FC14 may find much
broader use in GPCR study in the long run.
After achieving human FPR3 overexpression in stable
HEK293S cell line [29–31] and then selection of the suitable
detergent, we also successfully purified FPR3 to high homogeneity
by employing a two-step purification method [29–31]. We have
already obtained about ,2 mg FPR3 monomers from ,6 g
induced HEK293S cells [29–31]. Secondary structural analysis
showed that the purified FPR3 was correctly folded into
characteristic a-helix, similar as other known GPCRs. Crystalli-
zation trials have already been initiated on human FPR3.
Meanwhile, the constructed inducible cell lines are being grown
on a large-scale to obtain enough receptors for subsequent studies.
Our approach to produce a high yield of purified human FPR3
is a step forward toward obtaining a large quantity of this receptor
not only for structural and functional studies but also for
developing human FPR as therapeutic drug targets in the future.
Materials and Methods
Gene Construction
The 353 amino acid sequence of human FPR3 was obtained
from NCBI online database (accession number NP_002021.3). To
adapt the synthetic FPR3 gene for use in mammalian cell
expression, protein detection and purification, the following
sequence modifications were made: 1) human codon optimization;
2) addition of a C-terminal rho1D4 epitope tag (TETSQVAPA)
preceded by a GG linker to facilitate detection and purification; 3)
addition of a Kozak consensus sequence (GCCACCACC)
immediately 59 to the ATG start codon; 4) addition of an EcoRI
restriction site at the 59 end and an XhoI restriction site at the 39
end of the gene to enable cloning into expression vectors. The
FPR3 gene was then commercially synthesized and subcloned into
the T-REx pcDNA4/To inducible expression plasmid (Invitrogen,
Carlsbad, CA) by GENEART. The final construct was verified by
DNA sequencing and used for all subsequent studies.
Construction of Stable Inducible Cell Lines
The stable human FPR3-inducible HEK293S cell lines were
created as described before [29–31]. Briefly, HEK293S cells
containing the stable expression of pcDNA6/Tr (Invitrogen) were
grown in regular medium to form monolayers at 37uC at 5% CO2.
The pcDNA4/To plasmid containing the optimized human FPR3
gene was then transfected into these cells using Lipofectamine
2000. After 48 hours cells were subjected to drug selection in
5 mg/ml blasticidin and 50 mg/ml zeocin for 2–3 weeks, and then
subcloned with the zeocin concentration reduced to 25 mg/ml
from now on. 30 clones were expanded and screened for inducible
expression of human FPR3. For each clone, three parallel
expressions were tested: after 48 h in plain media (2) or media
supplemented with 1 mg/mL tetracycline (+) or tetracycline plus
2.5 mM sodium butyrate enhancer (++). Expression was assayed
via Dot blot and Western blot using the mouse monoclonal
antibody rho1D4. Clones showing the highest-level expression of
FPR3 under induction conditions while maintaining undetectable
expression without induction were selected and expanded into
large-scale culture and used for all subsequent experiments.
Systematic Detergent Screening
In total, 96 detergents/detergent mixtures were screened here,
with 88 detergents chosen from the Solution Master Detergent
Kit (Anatrace). Additionally, HEGA-10, NP-40, Digitonin and
five detergent mixtures were also chosen because of their
effectiveness in the solubilization of other GPCRs. More
information about each detergent/detergent mixture was pro-
vided in Table S1. The detergent screening process has been
described before [31].
Western Blot, Dot Blot and Total Protein Staining
Analyses
For Western blot, samples were first prepared and loaded in
Novex 10% Bis-Tris SDS-PAGE gel (Life Technologies) accord-
ing to manufacturer’s protocol, with the exception that the
samples were incubated at room temperature prior to loading as
boiling caused membrane protein aggregation. The Full Range
Rainbow (GE Healthcare, Waukesha, WI) molecular weight
marker was loaded as the protein size standard. After samples
were resolved on SDS-PAGE gel, they were transferred to a
0.45 mm nitrocellulose membrane, blocked in milk (5% non-fat
dried milk in TBST) for 1 hour, and incubated with a rho1D4
primary antibody (1:3000, 1 hour, room temperature). The target
proteins were then detected with a goat anti-mouse HRP-
conjugated secondary antibody (Pierce, Rockford, IL) (1:5000,
1 hour, room temperature) and visualized using the ECL-Plus Kit
(GE Healthcare). For Dot blot, 1 ml of each sample was directly
pipetted onto 0.45 mm nitrocellulose membrane. After air drying
for 20 minutes, the same procedures were performed for target
protein detection and visualization as in Western blot analysis.
For total protein staining, SDS-PAGE gels were run as described
above and then stained using silver staining (a much more
sensitive alternative to Coomassie; Invitrogen). All Western blot,
Dot blot and total protein staining images were captured using a
Fluor Chem gel documentation system (Alpha Innotech, San
Leandro, CA).
Immunoaffinity Purification and Gel Filtration Purification
For immunoaffinity purification, we utilized rho1D4 monoclo-
nal antibody (Cell Essentials, Boston, MA) chemically linked to
CNBr-activated Sepharose 4B beads (GE Healthcare). The
rho1D4 elution peptide Ac-TETSQVAPA-CONH2 was synthe-
sized by CPC Scientific Inc., CA. Rho1D4-Sepharose immunoaf-
finity purification has been described [30]. Gel filtration
chromatography was employed for further purification using a
HiLoad 16/60 Superdex 200 column on a A¨kta Purifier FPLC
system (GE Healthcare), as described before [30–31].
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Immunofluorescence analysis
Cells were plated at a low density in coverslip-bottomed 6-well
tissue culture plate. Mouse monoclonal rho1D4 antibody was
diluted 1:1200. Alexafluor-488 goat anti-mouse antibody (Invitro-
gen) was used at a 1:3000 dilution. Cells induced for 48 h in media
supplemented with 1 mg/ml tetracycline plus 2.5 mM sodium
butyrate were first fixed in 10% neutral buffered formalin solution
(Sigma-Aldrich) for 20 minutes at room temperature and then
permeabilized in ice-cold 1:1 acetone: methanol mixture at
220uC for 3 minutes. Cells were then blocked in PBS with
0.3 M glycine and 4% bovine serum albumin for 1 hour and
washed with PBS, followed by overnight incubation at 4uC in PBS
with 2% bovine serum albumin and mouse monoclonal rho1D4
antibody. After three washes with PBS, cells were then incubated
with Alexafluor-488 goat anti-mouse antibody for 1 hour and
washed with PBS. Cells were examined with a Nikon Eclipse
TE300 inverted microscope using excitation at 488 nm.
Secondary structural analysis using circular dichroism
Spectra were recorded at 15uC with a CD spectrometer (Aviv
Associates model 410). Far-UV CD spectra were measured over
the wavelength range of 195 nm to 260 nm with a step size of
1 nm and an averaging time of 5 seconds. Near-UV CD spectra
were measured over the wavelength range of 250 nm to 350 nm.
Spectra for purified human FPR3 monomers were blanked to
wash buffer. Spectra were collected with a 111-QS quartz sample
cell (Hellma) with a path length of 1 mm. The secondary structural
content was estimated by using the program K2D2 (www.ogic.ca/
projects/k2d2/). Raw data were first smoothed by using the built-
in smoothing function of Aviv software and the CD spectra shown
here were drawn from the smoothed data. A manual smoothing
was performed using 5-degree sliding polynomial.
Supporting Information
Table S1 A list of the detergents screened for optimal
solubilization of human FPR3 expressed in HEK293
cells.
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